Icecure Medical ( (ICCM) ) just unveiled an update.
On February 24, 2025, IceCure Medical announced it has filed for regulatory approval in Israel for its next-generation XSense™ Cryoablation System. This filing aligns with the global trend towards minimally invasive procedures and could significantly enhance the company’s market position by expanding the use of its technology across various medical fields. The XSense™ System, which has already received FDA approval in the U.S., aims to cater to a growing demand for non-surgical tumor treatment options, potentially impacting stakeholders positively by broadening the scope of medical applications and increasing market demand.
More about Icecure Medical
IceCure Medical, listed on Nasdaq as ICCM, specializes in developing and marketing advanced cryoablation therapy systems that utilize liquid-nitrogen to destroy tumors by freezing. The company’s primary focus areas include breast, kidney, bone, and lung cancer. Their minimally invasive technology offers a safe and efficient alternative to traditional surgical tumor removal and is marketed globally, including in the U.S., Europe, and China.
YTD Price Performance: 14.63%
Average Trading Volume: 457,435
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $79.76M
For a thorough assessment of ICCM stock, go to TipRanks’ Stock Analysis page.